Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib with Radiochemotherapy in Newly Diagnosed Malignant Glioma
NCT01220271Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2011
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of galunisertib in glioblastoma (GBM), malignant glioma, sponsored by Eli Lilly and Company. Started Apr 2011; status: completed.
02
Drugs
galunisertib
03
Conditions
glioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on NCT01220271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01220271.